Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn’s Disease: Post Hoc Analyses of VISIBLE Studies

BACKGROUND: Vedolizumab, an anti-α(4)β(7) integrin approved for intravenous (IV) treatment of moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD), was evaluated as a subcutaneous (SC) formulation in maintenance therapy for UC and CD in phase 3 VISIBLE 1, 2, and open-label...

Descripción completa

Detalles Bibliográficos
Autores principales: Sandborn, William J, Chen, Jingjing, Kisfalvi, Krisztina, Loftus, Edward V, D’Haens, Geert, Candela, Ninfa, Lasch, Karen, Wolf, Douglas C, Uddin, Sharif M, Danese, Silvio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Observations and Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10449415/
https://www.ncbi.nlm.nih.gov/pubmed/37636008
http://dx.doi.org/10.1093/crocol/otad034

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10449415/
https://www.ncbi.nlm.nih.gov/pubmed/37636008
http://dx.doi.org/10.1093/crocol/otad034

Ejemplares similares